Pre-clinical asthma and COPD models clearly demonstrate that enhancing endogenous antioxidant responses, particularly those mediated by Nrf2, can further enhance corticosteroid sensitivity. The gene discussed is NFE2L2; the disease is chronic obstructive pulmonary disease.